OneSource Specialty Pharma Q3 loss sends shares down 18%

Stock cracks after Q3 earnings disappointment

OneSource Specialty Pharma Ltd. shares fell sharply after the company reported a weak set of results for the December 2025 quarter (Q3 FY26). The stock slid as much as about 18% in intraday trade, touching around ₹1,164 on the BSE, which was also described as a 52-week low in market reports. The drop came despite a broader positive mood in the market on the day, indicating stock-specific selling. Investors reacted to a swing to losses, a sharp fall in revenue, and a steep decline in operating profitability. The company attributed the quarterly pressure largely to delays in customer approvals in Canada, which impacted the timing of revenue recognition. The key product cited in multiple reports was semaglutide, where regulatory approvals were delayed in Canada.

What the company reported for Q3 FY26

OneSource reported a net loss of ₹47 crore for Q3 FY26, reversing from a profit of ₹67 crore in the corresponding quarter last year, according to the coverage. Revenue from operations fell about 26% year-on-year (YoY) to around ₹290 crore, compared with about ₹393 crore in Q3 FY25. EBITDA for the quarter came in at about ₹17 crore, down 88% YoY from about ₹142 crore a year earlier. The EBITDA margin compressed to 6% from 36% in the year-ago period, a decline of 3,018 basis points. The company linked the margin pressure to lower revenue and a largely fixed cost base, which amplified the impact on profitability. It also said delays in customer approvals in Canada prolonged the transition from the MSA to the CSA phase, affecting the quarter’s operating performance.

Data points from trackers show a wider loss number too

Alongside the company’s reported ₹47 crore quarterly loss cited in the news flow, some market data trackers referenced a larger net loss figure for the December 2025 quarter. One dataset in the provided information showed net profit for Dec ’25 at ₹-88.7 crore, compared with ₹10.49 crore in Sep ’25. The same dataset listed revenue for Dec ’25 at ₹294.97 crore versus ₹378.8 crore in Sep ’25, and EBITDA at ₹14.86 crore versus ₹109.53 crore in Sep ’25. These figures point to a sharp sequential slowdown in addition to the YoY decline reported in the quarter. The article context does not reconcile the difference between the ₹47 crore loss and the ₹88.7 crore loss, so readers should treat them as figures cited from different sources in the same period.

Canada approvals and semaglutide delays at the centre

Across reports, the immediate trigger highlighted was delayed semaglutide approvals in Canada. The company said these delays affected sales recognition and margins during the quarter. Management commentary stated that the quarter was subdued because customer approvals in Canada took longer than expected, extending the MSA-to-CSA transition timeline. The company also pointed to its fixed cost structure as a reason the profitability impact was disproportionately large when revenue fell. In another note referenced in the provided text, weak traction in the non-drug development and compliance (DDC) business was cited as insufficient to offset the drop in DDC volumes linked to master contract agreements (MCAs). The company had also stopped taking incremental MCAs, which contributed to sequential revenue decline in that analysis.

What management said about demand and the order book

Neeraj Sharma, CEO and MD, said the subdued quarter was previously anticipated due to delays in customer approvals in Canada. He added that underlying demand remains intact, with the order book continuing to trend upwards. The company also flagged traction in its biologics segment, noting strong interest and that another global biosimilar player had been onboarded. Management said the funnel was at a “historic high” in the nascent biologics business, as cited in the text provided. These statements were positioned as an offset to near-term execution and approval delays that affected Q3.

The stock action: levels, ranges, and recent drawdown

The sharp Q3 reaction added to an already weak price trend cited in the material. One technical analyst note said the stock had fallen over 34% in the month and that the last couple of weeks were “extremely bearish,” suggesting investors stay on the sidelines until stabilisation. Another view cited a near-term trading range between ₹1,085 and ₹1,350, with a breakout above ₹1,350 potentially improving momentum. The stock was also described as down over 33% in January 2026 and about 41% over the last six months. Separately, the stock’s 52-week high was referenced at ₹2,249.65 in June 2025, highlighting the magnitude of the drawdown into the Q3 result.

Company snapshot: what OneSource does

OneSource Specialty Pharma Ltd. (BSE: 544292, NSE: ONESOURCE) is described as India’s first pure-play, multi-modality contract development and manufacturing organisation (CDMO) focused on complex specialty pharmaceuticals. The company was formerly known as Stelis Biopharma Limited and rebranded under OneSource Specialty Pharma to consolidate capabilities across biologics, drug-device combinations (DDC), sterile injectables, and oral technologies, including soft gelatin capsules. It listed in January 2025, and positions itself as an end-to-end CDMO partner for global pharma innovators, generics players, and biotech firms. The Q3 result, however, underlined how regulatory timelines and customer approvals can affect quarterly revenue recognition in such models.

Key numbers at a glance

Guidance reiterated despite the weak quarter

Despite the quarterly pressure, the company reaffirmed its FY28 guidance in the provided material. It expects organic revenue of $100 million, which could rise to $100 million including the proposed acquisition. EBITDA margin guidance was maintained at 40%. It also retained a leverage objective, targeting net debt to EBITDA below 1.5x. The reaffirmation was presented as a signal that the company views Q3 as affected by timing and approval delays rather than a change in long-term targets.

Why the quarter mattered for investors

The Q3 print was a clear reminder that regulatory approvals and customer sign-offs can create sharp swings in quarterly financials for CDMOs, particularly when fixed costs are significant. The magnitude of the EBITDA drop and margin compression, alongside the revenue decline, drove the market reaction more than the revenue miss alone. The Canada semaglutide approval timeline emerged as a key variable that investors were focused on, given its impact on sales recognition. With the stock already under pressure over recent months, the Q3 outcome intensified risk perception and brought technical levels into focus.

Conclusion

OneSource Specialty Pharma’s Q3 FY26 results triggered a steep sell-off, with the stock falling to around ₹1,164 as investors priced in a sharp profitability contraction and a swing to losses. The company attributed the quarter’s weakness to delays in customer approvals in Canada, including semaglutide, and reiterated FY28 guidance on revenue, margins, and leverage. The next set of updates investors are likely to watch will be management commentary and filings on approval timelines, conversion from MSA to CSA, and progress on the proposed acquisition embedded in the revenue guidance.